Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma.

Robertson VL, Anderson CS, Keller FG, Halkar R, Goodman M, Marcus RB, Esiashvili N.

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):324-32. doi: 10.1016/j.ijrobp.2010.02.002. Epub 2010 Jun 18.

PMID:
20646867
2.

Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma.

Paulino AC, Margolin J, Dreyer Z, Teh BS, Chiang S.

Pediatr Blood Cancer. 2012 Jun;58(6):860-4. doi: 10.1002/pbc.23273. Epub 2011 Aug 8.

PMID:
21826784
3.

Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin's disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition.

Metwally H, Courbon F, David I, Filleron T, Blouet A, Rives M, Izar F, Zerdoud S, Plat G, Vial J, Robert A, Laprie A.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):793-9. doi: 10.1016/j.ijrobp.2010.02.024. Epub 2010 Jul 7.

PMID:
20615626
4.

PET imaging in pediatric Hodgkin's lymphoma.

Hudson MM, Krasin MJ, Kaste SC.

Pediatr Radiol. 2004 Mar;34(3):190-8. Epub 2004 Jan 27. Review.

PMID:
14745528
5.

Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, Vitolo U, Mancini M, Bisi G, Gallo E.

Radiol Med. 2008 Jun;113(4):578-90. doi: 10.1007/s11547-008-0264-7. Epub 2008 Apr 14. English, Italian.

PMID:
18414808
6.

Staging in childhood lymphoma: differences between FDG-PET and CT.

Hermann S, Wormanns D, Pixberg M, Hunold A, Heindel W, Jürgens H, Schober O, Franzius C.

Nuklearmedizin. 2005 Feb;44(1):1-7.

PMID:
15711722
7.
8.

Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.

Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L.

Eur J Haematol. 2007 Mar;78(3):206-12. Epub 2007 Jan 23.

PMID:
17253974
9.

Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients.

Girinsky T, Aupérin A, Ribrag V, Elleuch M, Fermé C, Bonniaud G, Ruelle C, Alberini JL, Celebic A, Edeline V.

Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1047-52. doi: 10.1016/j.ijrobp.2014.04.026. Epub 2014 Jul 8.

PMID:
25035208
10.

Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT.

Weiler-Sagie M, Kagna O, Dann EJ, Ben-Barak A, Israel O.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1133-40. doi: 10.1007/s00259-014-2706-x. Epub 2014 Feb 26.

PMID:
24570095
11.

The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.

Qiu L, Chen Y, Wu J.

Hell J Nucl Med. 2013 Sep-Dec;16(3):230-6. doi: 10.1967/s0024499100091. Epub 2013 Oct 2. Review.

PMID:
24137577
12.

Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.

Cerci JJ, Pracchia LF, Soares Junior J, Linardi Cda C, Meneghetti JC, Buccheri V.

Clinics (Sao Paulo). 2009;64(6):491-8.

13.

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fosså A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW.

Blood. 2016 Mar 24;127(12):1531-8. doi: 10.1182/blood-2015-11-679407. Epub 2016 Jan 8.

14.
15.

A prospective study of ¹⁸FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies.

Terezakis SA, Schöder H, Kowalski A, McCann P, Lim R, Turlakov A, Gonen M, Barker C, Goenka A, Lovie S, Yahalom J.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):376-83. doi: 10.1016/j.ijrobp.2014.02.006. Epub 2014 Apr 11.

PMID:
24726287
16.

Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study.

Bakhshi S, Radhakrishnan V, Sharma P, Kumar R, Thulkar S, Vishnubhatla S, Dhawan D, Malhotra A.

Radiology. 2012 Mar;262(3):956-68. doi: 10.1148/radiol.11110936.

PMID:
22357895
17.

[18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.

Purz S, Mauz-Körholz C, Körholz D, Hasenclever D, Krausse A, Sorge I, Ruschke K, Stiefel M, Amthauer H, Schober O, Kranert WT, Weber WA, Haberkorn U, Hundsdörfer P, Ehlert K, Becker M, Rössler J, Kulozik AE, Sabri O, Kluge R.

J Clin Oncol. 2011 Sep 10;29(26):3523-8. doi: 10.1200/JCO.2010.32.4996. Epub 2011 Aug 8.

PMID:
21825262
18.

Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT.

Chiaravalloti A, Danieli R, Caracciolo CR, Travascio L, Cantonetti M, Gallamini A, Guazzaroni M, Orlacchio A, Simonetti G, Schillaci O.

Medicine (Baltimore). 2014 Aug;93(8):e50. doi: 10.1097/MD.0000000000000050.

19.

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.

Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, Elsner K, Frickhofen N, Reske SN, Bergmann L.

Ann Oncol. 1998 Oct;9(10):1117-22.

PMID:
9834825
20.

The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.

Paolini R, Rampin L, Rodella E, Ramazzina E, Banti E, Al-Nahhas A, Rubello D.

Nucl Med Rev Cent East Eur. 2007;10(2):87-90.

PMID:
18228212

Supplemental Content

Support Center